<DOC>
	<DOCNO>NCT00804947</DOCNO>
	<brief_summary>Analyze result ASCT use intravenous Busulfan Melphalan condition regimen patient Multiple Myeloma .</brief_summary>
	<brief_title>Autologous Stem Cell Transplant ( ASCT ) With Intravenous Busulfan Melphalan Conditioning Regimen</brief_title>
	<detailed_description>Primary Efficacy safety procedure term number remission , survival , event-free survival , relapse risk , early transplant-related mortality ( day +100 ) . Secondary Graft kinetics ( time neutrophil platelet recovery ASCT ) 2.Analyze presence transplant-related complication ( infection , sinusoidal occlusive syndrome others ) 3.Analyze prognostic factor engraftment , remission rate , relapse risk , disease-free overall survival ASCT</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Symptomatic multiple myeloma Male female subject age &gt; = 70 year The subject receive least one previous line therapy include : Frontline treatment VBMCP/VBAD VAD secondline therapy regimens include bortezomib , thalidomide lenalidomide The subject give voluntary write informed consent Use bortezomib , thalidomide lenalidomide frontline therapy ECOG satus &gt; =2 Left ventricular ejection fraction &lt; 40 % DLCO FVC &lt; 39 % theoretical value Abnormal liver function ( total bilirubin &gt; 2 mg/dL and/or ALT AST &gt; 3 x ULN ) Serum creatinine transplant &gt; 1.6 mg/dL and/or creatinine clearance &lt; 65 mL/minute Subject active systemic infection require treatment Subject myocardial infarction within 6 month enrollment NYHA Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrythmias Subject serious medical condition ( severe hepatic impairment , pericardial disease , acute diffuse infiltrative pulmonary disease ) psychiatric illness could potentially interfere completion treatment protocol Subject know immunodeficiency virus ( HIV ) positive Subject receive experimental drug use experimental medical device within 4 week enrollment If female , subject pregnant breastfeeding . Confirmation subject pregnant must establish negative pregnancy test screening . Pregnancy test require postmenopausal surgically sterilize woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Autologous transplantation</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Intravenous Busulfan</keyword>
</DOC>